Harmonizing pharmaceutical product labeling (i.e., using identical labeling across multiple countries) can create time and cost efficiencies that benefit stakeholders across the value chain. Despite the clear benefits, there is little publicly available information for suppliers who want to pursue harmonized labeling for their products.
In this webinar, held on March 22, 2002, presenters discussed efforts led by Impact RH360/Medicines360, WCG Cares, and FHI 360 to develop a strategy for harmonizing labeling for Impact RH360’s hormonal IUD product, Avibela. Insights from this assessment may be helpful for suppliers, regulatory experts, procurers, and others who seek to harmonize labeling for global health products.
The webinar recording is below and the full initiative brief can be accessed though our resource library here. You can also learn more about these efforts in a recently blog post from Medicines360's Kelly Dannucci here.
Presenters:
Emily Morris, Associate Director, Regulatory Affairs, Impact RH360/Medicines360
Kelly Dannucci, Sr. Manager, Global Access, Impact RH360/Medicines360
Mark Busch, SVP, Quality Assurance & Product Safety, Impact RH360/Medicines360
Wilberto Robles, Sr. Director, Global Regulatory Affairs & Quality Assurance, WCG Cares
Moderator:
Kate Rademacher, Senior Technical Advisor, FHI 360
This event was hosted by the Reproductive Health Supplies Coalition (RHSC), the Hormonal IUD Access Group, and the Contraceptive Technology Innovation (CTI) Exchange.
For more information about global efforts to expand access to the hormonal IUD, visit: https://www.hormonaliud.org